In a patient with no family history of bleeding disorders, no cancer, and no prior deep‑vein thrombosis, can a laparoscopic myomectomy provoke a sudden DVT and how should it be managed?

Yes, Laparoscopic Myomectomy Can Absolutely Cause DVT—Even in Low-Risk Patients

Any major abdominopelvic surgery, including laparoscopic myomectomy, carries inherent VTE risk regardless of personal or family history, and this patient requires immediate therapeutic anticoagulation and risk stratification for extended prophylaxis.

Why "Minor Surgery" Is a Misconception

Laparoscopic myomectomy is not a minor surgery from a thrombotic standpoint. The procedure involves:

• Pneumoperitoneum: Increased intra-abdominal pressure (12-15 mmHg) that compresses pelvic and lower extremity veins, reducing venous return by up to 50% 1
• Trendelenburg positioning: Further impairs venous drainage from lower extremities 1
• Surgical trauma: Activates the coagulation cascade regardless of incision size 1
• Postoperative hypercoagulability: Persists for 30 days after major abdominopelvic surgery 2

The laparoscopic approach does not eliminate VTE risk—studies show similar DVT rates between laparoscopic and open gynecologic surgery when prophylaxis is standardized 3.

Risk Stratification Using Caprini Score

Even without traditional risk factors, this patient likely has a moderate-to-high Caprini score (≥3-5) based on:

• Major surgery (laparoscopic myomectomy) = 2-3 points
• Age (if >40 years) = 1-2 points
• Operative time (if >2-6 hours) = 2-5 points
• Large uterine fibroids (if uterus ≥1000g) = additional risk 4

A Caprini score ≥5 places her in the high-risk category with ~6% baseline VTE risk 5. The absence of family history or prior DVT does not negate surgical risk factors.

Immediate Management of Acute DVT

1. Confirm diagnosis: Compression ultrasound of entire lower extremity (proximal and distal veins)

2. Initiate therapeutic anticoagulation immediately:

   • First-line: Direct oral anticoagulant (DOAC)—apixaban 10mg BID × 7 days, then 5mg BID; or rivaroxaban 15mg BID × 21 days, then 20mg daily 6, 7
   • Alternative: Low molecular weight heparin (LMWH) if DOAC contraindicated 6

3. Rule out pulmonary embolism: If any dyspnea, chest pain, tachycardia, or hypoxia—obtain CT pulmonary angiography 7

4. Assess bleeding risk: Recent surgery increases bleeding risk, but therapeutic anticoagulation is still indicated unless active bleeding or high bleeding risk contraindications exist 6

Duration of Anticoagulation

Minimum 3 months of therapeutic anticoagulation is required for provoked DVT 7, 8. However, consider:

• Extended prophylaxis (up to 28 days post-op) would have been appropriate given her surgical risk profile 2
• Since DVT already occurred, she needs full therapeutic anticoagulation, not just prophylaxis
• After 3 months, reassess: if isolated distal DVT with complete resolution and no residual risk factors, may discontinue; if proximal DVT or persistent risk factors, consider extended therapy 6, 8

Key Clinical Pitfalls

Common mistake: Assuming laparoscopic = low risk. The pneumoperitoneum and positioning create unique thrombogenic conditions that offset the benefits of smaller incisions 1.

Common mistake: Relying on family history. Most postoperative VTE is provoked by surgery itself, not inherited thrombophilia. Only 20-30% of VTE patients have identifiable genetic risk factors 7.

Common mistake: Inadequate prophylaxis. Guidelines recommend pharmacologic prophylaxis (LMWH or LDUH) for moderate-to-high risk gynecologic surgery patients, yet implementation remains suboptimal 5, 9. This patient should have received:

• Preoperative or early postoperative LMWH (enoxaparin 40mg daily or equivalent) 9
• Mechanical prophylaxis (intermittent pneumatic compression) 9
• Early mobilization
• Extended prophylaxis for 28 days if Caprini score ≥5 or additional risk factors present 2

Special Considerations for Gynecologic Surgery

Large uterine fibroids (≥1000g or adult head-sized on exam) independently increase DVT risk to 11.5% vs. 3% for smaller fibroids 4. Operative time >6 hours significantly increases PE risk 3. These procedure-specific factors compound baseline surgical risk.

The symptomatic VTE rate after gynecologic MIS is 0.2-1.8% even with prophylaxis 3, but asymptomatic DVT rates are much higher (up to 20% without screening) 9. This patient's "sudden" presentation likely represents progression of perioperative thrombus formation that began during or immediately after surgery.

Bottom Line

This DVT is a direct complication of her surgery, not a spontaneous event. Treat aggressively with therapeutic anticoagulation, investigate for PE, and recognize that inadequate perioperative prophylaxis likely contributed to this outcome. The absence of traditional risk factors does not protect against surgery-provoked VTE.